Gilead Sciences (GILD) : Fjarde Ap-fonden Fourth Swedish National Pension Fund scooped up 295 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 14, 2016. The investment management firm now holds a total of 313,465 shares of Gilead Sciences which is valued at $22,804,579.Gilead Sciences makes up approximately 0.51% of Fjarde Ap-fonden Fourth Swedish National Pension Fund’s portfolio.
Other Hedge Funds, Including , Charter Trust Co boosted its stake in GILD in the latest quarter, The investment management firm added 5,958 additional shares and now holds a total of 19,241 shares of Gilead Sciences which is valued at $1,399,783. Gilead Sciences makes up approx 0.16% of Charter Trust Co’s portfolio.Howland Capital Management reduced its stake in GILD by selling 5,303 shares or 2.05% in the most recent quarter. The Hedge Fund company now holds 253,307 shares of GILD which is valued at $18,506,609. Gilead Sciences makes up approx 1.76% of Howland Capital Management’s portfolio.Alta Capital Management reduced its stake in GILD by selling 12,746 shares or 6.09% in the most recent quarter. The Hedge Fund company now holds 196,448 shares of GILD which is valued at $14,352,491. Gilead Sciences makes up approx 0.91% of Alta Capital Management’s portfolio.Banced Corp reduced its stake in GILD by selling 503 shares or 3.64% in the most recent quarter. The Hedge Fund company now holds 13,317 shares of GILD which is valued at $983,061. Gilead Sciences makes up approx 1.95% of Banced Corp’s portfolio.Nisa Investment Advisors reduced its stake in GILD by selling 12,432 shares or 2.42% in the most recent quarter. The Hedge Fund company now holds 501,404 shares of GILD which is valued at $37,013,643. Gilead Sciences makes up approx 0.49% of Nisa Investment Advisors’s portfolio.
Gilead Sciences closed down -0.31 points or -0.42% at $72.75 with 73,59,055 shares getting traded on Friday. Post opening the session at $73.27, the shares hit an intraday low of $72.73 and an intraday high of $73.5 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by RBC Capital Mkts on Oct 3, 2016 to “Outperform” and Lowered the Price Target to $ 95 from a previous price target of $105 .Shares were Downgraded by Leerink Partners on Sep 27, 2016 to ” Mkt Perform” and Lowered the Price Target to $ 94 from a previous price target of $112 .Berenberg Initiated Gilead Sciences on Sep 12, 2016 to “Buy”, Price Target of the shares are set at $112.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.